
CGON Stock Forecast & Price Target
CGON Analyst Ratings
Bulls say
CG Oncology Inc. is positioned for significant revenue growth, with projected launch sales of its candidate, cretostimogene grenadenorepvec, anticipated to reach approximately $2.6 billion by 2034. The company's emphasis on differentiated efficacy and durability, as suggested by the promising data from its clinical trials, indicates strong potential for treatment adoption among physicians and patients, addressing the unmet need for next-generation therapies targeting NMIBC. Additionally, the successful navigation of regulatory pathways and management's confidence in manufacturing readiness further strengthens the outlook for Creto's commercialization and market presence.
Bears say
The financial analysis highlights several concerns regarding CG Oncology's stock, primarily focusing on competitive positioning and potential market risks. The history of other oncology products, such as Zaltrap against Avastin, indicates that lack of differentiation in effectiveness can lead to poor market performance, which could equally affect CG Oncology if its therapy does not demonstrate substantial advantages. Additionally, the risk of negative trial outcomes, slow enrollment, and potential regulatory hurdles raises serious doubts about the company’s timeline for commercialization and market potential, further undermining investor confidence.
This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
CGON Analyst Forecast & Price Prediction
Start investing in CGON
Order type
Buy in
Order amount
Est. shares
0 shares